:: Posted by American Biotechnologist on 11-20-2012
Pathway analysis provides an efficient and focused approach for studying a large number of related gene targets in a single experiment. The pathway curation and ranking strategy employed by Thomson Reuters and Bio-Rad ensures that the gene assays present on each real-time PCR pathway and collection panel are the most relevant for gene expression profiling based on differential expression studies and the frequency with which gene targets appear in the peer-reviewed literature. All PrimePCR assays were designed following strict guidelines on maximum transcript coverage, have minimal overlap with known single nucleotide polymorphisms, and span large introns where possible. In addition, they have all been fully validated in the lab, passing stringent quality controls. As a result, PrimePCR panels set a new quality standard for commercially available predesigned qPCR pathway panels.
Click here to read the full article in Bioradiations.
Click on the pathway map below to view a larger version.
Apoptosis and survival — TNF-R1 signaling pathway map. This pathway map is one example of the 260 canonical pathway maps provided by Thomson Reuters. Pathway maps illustrate protein interactions and regulation to provide a comprehensive picture of signaling and disease processes. On the Bio-Rad website, each target on the map can be selected to view corresponding gene and protein information.
:: Posted by American Biotechnologist on 09-04-2012
Well…you heard it here first folks. Last week we told you about Bio-Rad Laboratories new line of pre-validated, MIQE friendly qPCR assays and how this is bound to save researchers troubleshooting time and frustration (see MIQE Trouble-Free). Now the story has made the news. According to the story on GenomeWeb, Bio-Rad’s launch of PrimePCR has given the company the distinct advantage of being the only vendor whose entire portfolio of qPCR assays has been validated to such standards. The company expects the assays, which cover approximately 95 percent of the human transcriptome, to save researchers time and resources by obviating the need to validate assays in their own laboratories.
Click here to read the rest of the story (subscription required).